2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 284

Metabolic Activity Sustains Macrophage Cytokine Production in Rheumatoid Arthritis and Coronary Artery Disease
Abstract Number: 285

Liver X Receptor-α (LXRα) Modulates Macrophage Phenotype and Disease Activity in SLE
Abstract Number: 286

Serum Amyloid a Aggravates Rheumatoid Arthritis By Activating NFAT5-Mediated Migration of Macrophages
Abstract Number: 287

Anti-TNF Agents Induce Alternative Macrophages
Abstract Number: 288

The Rheumatoid Arthritis Susceptibility Gene C5orf30 Is an Immunomodulator in Macrophages
Abstract Number: 289

HDL Modified with Malondialdehyde-Acetaldehyde (MAA) Is Bound and Rapidly Internalized By Human THP-1 Monocytes
Abstract Number: 290

Characterization of Neutrophil Subsets and Neutrophil Extracellular Traps in Pyogenic Arthritis, Pyoderma Gangrenosum and Acne (PAPA) Syndrome
Abstract Number: 291

A Novel Real-Time Imaging Technique to Quantify Neutrophil Extracellular Traps and Distinguish Mechanisms of Cell Death in Neutrophils
Abstract Number: 292

Neutrophil Extracellular Traps Are Induced By Adenosine and Stimulate Release of TNF Alpha from Macrophages in Deficiency of Adenosine Deaminase 2 (DADA2)
Abstract Number: 293

Expanded Therapeutic ACPA Utility for Different NET-Driven Human (Autoimmune) Diseases
Abstract Number: 294

DNA Area and Netosis Analysis (DANA): A High-Throughput Method to Quantify Neutrophil Extracellular Traps in Fluorescent Microscope Images
Abstract Number: 295

Ex Vivo Induced Neutrophil Extracellular Traps Are Intrinsically Different in Anca-Associated Vasculitis and Systemic Lupus Erythematosus
Abstract Number: 296

A Module of Genes Describing Low Density Granulocytes Can be Identified and Followed in the Periphery of Lupus Patients
Abstract Number: 297

Multiplexed Characterization of Circulating and Joint-Derived Human Neutrophils in Inflammatory Arthritis
Abstract Number: 298

Anabasum (JBT-101) Enhances Resolution of Inflammation in Humans

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].